Gamco Investors INC. ET AL lifted its position in Allergan (NYSE:AGN) by 8.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 73,453 shares of the company’s stock after purchasing an additional 5,505 shares during the period. Gamco Investors INC. ET AL’s holdings in Allergan were worth $12,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Allergan by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 3,422,365 shares of the company’s stock worth $558,625,000 after purchasing an additional 72,303 shares in the last quarter. Parnassus Investments CA boosted its position in shares of Allergan by 20.4% during the fourth quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock worth $353,633,000 after acquiring an additional 365,914 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Allergan by 17.9% during the first quarter. Wells Fargo & Company MN now owns 1,826,952 shares of the company’s stock worth $307,457,000 after acquiring an additional 277,702 shares during the last quarter. UBS Asset Management Americas Inc. boosted its position in shares of Allergan by 13.6% during the fourth quarter. UBS Asset Management Americas Inc. now owns 1,763,209 shares of the company’s stock worth $288,426,000 after acquiring an additional 210,962 shares during the last quarter. Finally, Iridian Asset Management LLC CT boosted its position in shares of Allergan by 4.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 1,712,404 shares of the company’s stock worth $280,115,000 after acquiring an additional 78,455 shares during the last quarter. 79.57% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on AGN shares. Cowen set a $255.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Monday, April 16th. SunTrust Banks started coverage on shares of Allergan in a research report on Friday, February 23rd. They set a “buy” rating and a $200.00 target price for the company. They noted that the move was a valuation call. Vetr upgraded shares of Allergan from a “sell” rating to a “hold” rating and set a $189.60 target price for the company in a research report on Friday, January 26th. Royal Bank of Canada restated a “buy” rating and set a $213.00 target price on shares of Allergan in a research report on Wednesday, March 14th. Finally, Credit Suisse Group set a $215.00 target price on shares of Allergan and gave the stock a “buy” rating in a research report on Sunday, April 22nd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $214.81.
Allergan opened at $154.00 on Friday, Marketbeat.com reports. Allergan has a 52 week low of $142.81 and a 52 week high of $256.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.10 and a quick ratio of 0.94. The firm has a market cap of $52.10 billion, a price-to-earnings ratio of 9.42, a price-to-earnings-growth ratio of 1.10 and a beta of 1.17.
Allergan (NYSE:AGN) last released its quarterly earnings data on Monday, April 30th. The company reported $3.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.36 by $0.38. Allergan had a negative net margin of 11.94% and a positive return on equity of 8.53%. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same quarter last year, the business earned $3.35 earnings per share. Allergan’s quarterly revenue was up 2.8% compared to the same quarter last year. research analysts anticipate that Allergan will post 16.03 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 15th. Stockholders of record on Friday, May 18th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Thursday, May 17th. This represents a $2.88 annualized dividend and a dividend yield of 1.87%. Allergan’s dividend payout ratio (DPR) is presently 17.61%.
In other news, CEO Brent L. Saunders bought 3,300 shares of the stock in a transaction dated Thursday, March 8th. The stock was purchased at an average price of $152.53 per share, for a total transaction of $503,349.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP William Meury sold 24,425 shares of the firm’s stock in a transaction dated Thursday, May 17th. The stock was sold at an average price of $154.59, for a total transaction of $3,775,860.75. The disclosure for this sale can be found here. Insiders bought a total of 6,095 shares of company stock valued at $936,201 in the last 90 days. Company insiders own 0.36% of the company’s stock.
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.